Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of $1.23 per share and revenue of $37.84 million for the quarter.
Ligand Pharmaceuticals Trading Down 2.8 %
LGND stock traded down $3.03 during midday trading on Tuesday, reaching $103.32. The stock had a trading volume of 95,800 shares, compared to its average volume of 119,258. The company has a market cap of $1.99 billion, a price-to-earnings ratio of 41.16 and a beta of 0.87. Ligand Pharmaceuticals has a 52-week low of $72.95 and a 52-week high of $129.90. The company's fifty day simple moving average is $107.34 and its 200 day simple moving average is $112.50.
Insider Buying and Selling at Ligand Pharmaceuticals
In other news, CFO Octavio Espinoza sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $115.03, for a total transaction of $575,150.00. Following the completion of the sale, the chief financial officer now owns 18,879 shares in the company, valued at approximately $2,171,651.37. The trade was a 20.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.90% of the stock is owned by insiders.
Analyst Ratings Changes
Several research analysts have recently weighed in on LGND shares. Stifel Nicolaus began coverage on Ligand Pharmaceuticals in a report on Thursday, April 10th. They set a "buy" rating and a $143.00 target price on the stock. StockNews.com upgraded shares of Ligand Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Tuesday, April 15th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, Ligand Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $146.43.
Read Our Latest Research Report on Ligand Pharmaceuticals
About Ligand Pharmaceuticals
(
Get Free Report)
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
See Also
Before you consider Ligand Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ligand Pharmaceuticals wasn't on the list.
While Ligand Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
